Targeted Delivery of Paclitaxel-Loaded Bovine Serum Albumin Nanoparticles: A Potential Cancer Treatment

Strategic Insights -

Researchers at Northeast Forestry University in China have developed a novel targeted delivery system for the cancer treatment drug paclitaxel. By decorating paclitaxel-loaded bovine serum albumin nanoparticles with folic acid, the researchers were able to effectively target human prostate cancer cells in vitro. The study, published in the International Journal of Nanomedicine, demonstrates the potential of this targeted delivery system in treating various cancers.

Key Takeaways:

  • Paclitaxel is a widely used anticancer drug with low solubility, which is formulated in high concentration in Cremophor EL, causing hypersensitivity reactions.
  • The researchers developed a method to prepare targeted delivery of paclitaxel-loaded nanoparticles using a desolvation procedure and crosslinking on the wall material of bovine serum albumin.
  • The nanoparticles were characterized with a zeta potential of about -30 mV and a size of around 210 nm with a narrow size distribution.
  • The drug entrapment efficiency and drug loading efficiency were approximately 95.3% and 27.2%, respectively.
  • The amount of folate conjugation on the surface of the nanoparticles was 9.22 g/mg of bovine serum albumin.
  • The folate-decorated nanoparticles were able to effectively target human prostate cancer cells in vitro.
  • D. Zhao and colleagues, Northeast Forestry University, are the authors of the study, which was published in the International Journal of Nanomedicine in 2010.

Statistics:

  • 95.3%: Drug entrapment efficiency of the paclitaxel-loaded nanoparticles.
  • 27.2%: Drug loading efficiency of the paclitaxel-loaded nanoparticles.
  • 9.22 g/mg: Amount of folate conjugation on the surface of the bovine serum albumin nanoparticles.
  • 210 nm: Average size of the nanoparticles.
  • -30 mV: Zeta potential of the nanoparticles.

Sources:

  • Zhao, D., et al. "Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles." International Journal of Nanomedicine, 2010; 5(): 669-77.